Vertex Pharmaceuticals Incorporated (FRA:VX1)
Germany
· Delayed Price · Currency is EUR 391.80
-3.90 (-0.99%)
At close: Dec 5, 2025
Revenue
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Trikafta / Kaftrio Revenue | 10.46B | 10.24B |
Log In |
Log In |
Log In | Upgrade
|
| Symdeko / Symkevi Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Orkambi Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Kalydeco Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Casgevy Revenue | 69.50M | 10.00M |
Log In |
Log In |
Log In | Upgrade
|
| Other Product Revenue | 773.90M | 781.50M |
Log In |
Log In |
Log In | Upgrade
|
| Net Product Revenue | 11.69B | 11.02B |
Log In |
Log In |
Log In | Upgrade
|
| Other Collaborative and Royalty Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Other) | -11.30B | -11.03B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 11.69B | 11.02B |
Log In |
Log In |
Log In | Upgrade
|
| Other Collaborative and Royalty Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Other Collaborative and Royalty Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Other Collaborative and Royalty Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| United States Product Revenue | 7.29B | 6.68B |
Log In |
Log In |
Log In | Upgrade
|
| Outside of United States Product Revenue | 4.40B | 4.34B |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 11.69B | 11.02B |
Log In |
Log In |
Log In | Upgrade
|